RARE DISEASE
Anterior uveitis
Anterior uveitis
Anterior uveitis
Synonyms: Iridocyclitis
Synonyms: Iridocyclitis
Synonyms: Iridocyclitis
Drug discovery
2
drugs
With orphan designations
Overview
Anterior uveitis (AU) is the most common form of uveitis, characterized by inflammation of the iris and ciliary body. Symptoms include ocular pain, photophobia, blurred vision, and conjunctival redness, often presenting acutely but may become chronic or recurrent. Up to 52% of cases have systemic associations, including HLA-B27-related spondyloarthropathies or infections like herpesviruses. Diagnosis requires slit-lamp evaluation for anterior chamber cells/flare and targeted testing for etiology [1][6][11].
Burden
Responsible for 10% of legal blindness in the US, with complications including glaucoma (20%), cataracts, and cystoid macular edema [1][16].
Annual US healthcare costs exceed $241 million, driven by frequent monitoring (5-7 visits per acute episode) and biologics [8][13].
Chronic cases incur 2.5x higher productivity losses vs controls due to visual impairment [16][17].
Therapies
First-line: Aggressive topical corticosteroids (e.g., prednisolone acetate 1% hourly) and cycloplegics (e.g., cyclopentolate) [1][3][11].
Refractory cases: Periocular/intravitreal steroids (triamcinolone) or systemic immunomodulators (methotrexate, adalimumab) [8][13][18].
Infectious causes: Antivirals (acyclovir/valacyclovir for herpesviruses) with concurrent steroids [5][11].
Categories: rare ophthalmic disorders
Research Papers
1,264 drug discovery papers about Anterior uveitis, with 3 first-in-class and 11 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,264 drug discovery papers about Anterior uveitis, with 3 first-in-class and 11 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-30 | AYURVEDIC MANAGEMENT OF ACUTE ANTERIOR UVEITIS (PITTAJA ADHIMANTHA): A CASE REPORT
Introduction: Uveitis is an inflammatory disorder of the vascular layer of the eyeball and accounts for approximately 10% of blindness. Anterior uveitis denotes inflammation of the iris and/or the anterior part of the ciliary body and is characterized by pain, photophobia, ciliary congestion, blurred vision and keratic precipitates; if not treated promptly it can cause complications such as glaucoma, cataract, cystoid macular oedema and retinal detachment. Case presentation: A 40‑year‑old male presented with bilateral ocular pain, redness, watering, photophobia and blurred vision for 4–5 days, diagnosed as anterior uveitis and correlated with Pittaja Adhimantha according to Ayurveda. He was treated with Jalaukavacharana (leech therapy) on day 1 and day 7 along with internal medications: Gokshuradi Guggulu 250 mg – 2 tablets twice daily for 7 days, a ghrita preparation 3 g twice daily for 7 days, Saptamrita Lauha 1 tablet twice daily for 15 days and Triphala Avaleha 1 teaspoon once daily for 15 days. Results: By the third day of treatment, ocular pain, redness, photophobia, watering and blurring of vision had reduced by about 50% compared with baseline, and by the seventh day the patient became completely asymptomatic. Conclusion: The combination of Jalaukavacharana with internal Pitta‑shamana medicines including Gokshuradi Guggulu, ghrita, Saptamrita Lauha and Triphala Avaleha proved effective in this case of acute anterior uveitis (Pittaja Adhimantha), suggesting a useful Ayurvedic alternative or adjunct to steroid‑based management.
2026-07-19 | AYURVEDIC MANAGEMENT OF RECURRENT ANTERIOR UVEITIS (RAKTAJA AD-HIMANTHA): A CASE STUDY
A 40-year-old male patient came to the Ophthalmology OPD in December 2025 with complaints of redness, water-ing (epiphora), blurred vision and pain in the left eye for the last 5-7 days. On detailed history-taking, the patient reported that similar episodes had recurred every 15-20 days over the past year, significantly affecting daily functioning. Based on clinical signs, symptoms, and Ayurvedic diagnostic pa-rameters, the condition was diagnosed as Raktaja Adhimantha. The patient was managed with an Ayurvedic thera-peutic protocol comprising Jalaukavacharana (leech therapy), Netraseka, and oral Ayurvedic medicines. The symp-toms resolved within 21 days, and the anterior chamber findings returned to normal after almost one month. Oral medication was continued for two months. Patient remains symptom-free for four months. Thereafter, no recur-rence was noticed till May 2026. Raktamokshana, along with netraseka and oral medication, is effective in recur-rent anterior uveitis.
2026-07-18 | Treatment of spontaneous hyphema in Fuch's heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab.
Fuch's heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler's sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.
2026-07-08 | Long-term structural impact and antiviral efficacy of cytomegalovirus anterior uveitis - results from a 10-year ocular inflammation registry.
To evaluate criteria-based long-term structural outcomes and dose-dependent antiviral effects in cytomegalovirus anterior uveitis (CMV AU). From a 10-year ocular inflammation registry comprising 1,404 patients, 79 eyes from 67 patients with PCR-confirmed CMV AU were identified (mean follow-up, 48 ± 38 months). Serial assessments included retinal nerve fiber layer (RNFL) thickness, corneal endothelial cell density (ECCD), and visual field testing. Criteria for manifest glaucoma were defined as RNFL ≤ 75 μm, interocular asymmetry ≥ 15 μm, or visual field defects; manifest ECCD loss as ≥ 20% interocular difference or ECCD ≤ 1500 cells/mm². Initial treatment response (ITR) was defined as IOP normalization and inflammation reduction within 2 weeks. Flare-up rates were compared between high-dose (2% ganciclovir ≥ QID) and low-dose (2% ganciclovir ≤ TID) topical regimens. The mean age was 56.5 ± 15.5 years, and 82.1% had unilateral disease. Median diagnostic delay was 33 months; 20.9% required repeat aqueous taps. ITR was achieved in 87.6%. High-dose topical antivirals reduced flare-ups 2.25-fold vs. low-dose regimens (0.471 vs. 1.058 events/eye-year; relative risk = 0.45). Glaucoma rose from 30.3% to 62.0% and ECCD loss from 27.8% to 57.0% during follow-up. Kaplan-Meier analysis showed a median time of 9 years from symptom-onset to manifest glaucoma. Above-midline KPs were inversely associated with peak IOP on linear regression (p < 0.001). CMV AU poses significant long-term structural risk despite good short-term control. Early criteria-based treatment and high-dose antivirals reduce relapse, while lifelong maintenance is required in eyes with advanced disease.
2026-06-27 | Statin Intensity and the Risk of Noninfectious Uveitis.
To evaluate whether the 5-year risk of incident noninfectious uveitis (NIU) is associated with the intensity of statin therapy in patients with hyperlipidemia. Retrospective, propensity score-matched cohort study. Patients diagnosed with hyperlipidemia within a nationwide federated electronic medical record network (TriNetX). Patients initiating high-, medium-, or low-intensity statin therapy were compared to two mutually exclusive control cohorts: an active comparator control (proton pump inhibitor [PPI] users) and an unexposed control cohort. Patients with prior uveitis or any history of fibrate use were excluded. Each statin intensity cohort underwent 1:1 propensity score matching with both control groups to balance baseline demographics and systemic comorbidities. 5-year hazard ratios (HR) with 95% confidence intervals (CI) for incident overall NIU, anterior uveitis, and posterior/panuveitis. Prior to matching, the study identified 32,434 high-intensity, 16,955 medium-intensity, and 4,843 low-intensity statin users. Following matching, high-intensity statin therapy was associated with a significantly reduced 5-year risk of overall NIU compared to the unexposed control (HR 0.81, 95% CI: 0.69-0.95) with a statistically significant reduction against the active control (HR 0.73, 95% CI: 0.57-0.94). This protective effect was primarily driven by significant reductions in anterior uveitis against both the unexposed control (HR 0.77, 95% CI: 0.65-0.92) and the active control (HR 0.72, 95% CI: 0.55-0.94). Medium-intensity statin therapy yielded a significant risk reduction for overall NIU (HR 0.81, 95% CI: 0.66-0.99) and anterior uveitis (HR 0.84, 95% CI: 0.68-1.03) against the unexposed control but did not reach statistical significance against the active control. Low-intensity statin regimens did not significantly alter the risk of NIU or any anatomical subtype across either comparison group. Negative control outcome analysis demonstrated null associations across all cohorts, supporting the validity of the observed findings. Statin therapy is associated with an intensity-dependent reduction in the 5-year risk of noninfectious uveitis. High-intensity statin regimens confer the most robust and sustained protective benefit, suggesting that higher-potency dosing is necessary to achieve clinically significant modulation of ocular inflammation.
2026-07-30 | AYURVEDIC MANAGEMENT OF ACUTE ANTERIOR UVEITIS (PITTAJA ADHIMANTHA): A CASE REPORT
Introduction: Uveitis is an inflammatory disorder of the vascular layer of the eyeball and accounts for approximately 10% of blindness. Anterior uveitis denotes inflammation of the iris and/or the anterior part of the ciliary body and is characterized by pain, photophobia, ciliary congestion, blurred vision and keratic precipitates; if not treated promptly it can cause complications such as glaucoma, cataract, cystoid macular oedema and retinal detachment. Case presentation: A 40‑year‑old male presented with bilateral ocular pain, redness, watering, photophobia and blurred vision for 4–5 days, diagnosed as anterior uveitis and correlated with Pittaja Adhimantha according to Ayurveda. He was treated with Jalaukavacharana (leech therapy) on day 1 and day 7 along with internal medications: Gokshuradi Guggulu 250 mg – 2 tablets twice daily for 7 days, a ghrita preparation 3 g twice daily for 7 days, Saptamrita Lauha 1 tablet twice daily for 15 days and Triphala Avaleha 1 teaspoon once daily for 15 days. Results: By the third day of treatment, ocular pain, redness, photophobia, watering and blurring of vision had reduced by about 50% compared with baseline, and by the seventh day the patient became completely asymptomatic. Conclusion: The combination of Jalaukavacharana with internal Pitta‑shamana medicines including Gokshuradi Guggulu, ghrita, Saptamrita Lauha and Triphala Avaleha proved effective in this case of acute anterior uveitis (Pittaja Adhimantha), suggesting a useful Ayurvedic alternative or adjunct to steroid‑based management.
2026-07-19 | AYURVEDIC MANAGEMENT OF RECURRENT ANTERIOR UVEITIS (RAKTAJA AD-HIMANTHA): A CASE STUDY
A 40-year-old male patient came to the Ophthalmology OPD in December 2025 with complaints of redness, water-ing (epiphora), blurred vision and pain in the left eye for the last 5-7 days. On detailed history-taking, the patient reported that similar episodes had recurred every 15-20 days over the past year, significantly affecting daily functioning. Based on clinical signs, symptoms, and Ayurvedic diagnostic pa-rameters, the condition was diagnosed as Raktaja Adhimantha. The patient was managed with an Ayurvedic thera-peutic protocol comprising Jalaukavacharana (leech therapy), Netraseka, and oral Ayurvedic medicines. The symp-toms resolved within 21 days, and the anterior chamber findings returned to normal after almost one month. Oral medication was continued for two months. Patient remains symptom-free for four months. Thereafter, no recur-rence was noticed till May 2026. Raktamokshana, along with netraseka and oral medication, is effective in recur-rent anterior uveitis.
2026-07-18 | Treatment of spontaneous hyphema in Fuch's heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab.
Fuch's heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler's sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.
2026-07-08 | Long-term structural impact and antiviral efficacy of cytomegalovirus anterior uveitis - results from a 10-year ocular inflammation registry.
To evaluate criteria-based long-term structural outcomes and dose-dependent antiviral effects in cytomegalovirus anterior uveitis (CMV AU). From a 10-year ocular inflammation registry comprising 1,404 patients, 79 eyes from 67 patients with PCR-confirmed CMV AU were identified (mean follow-up, 48 ± 38 months). Serial assessments included retinal nerve fiber layer (RNFL) thickness, corneal endothelial cell density (ECCD), and visual field testing. Criteria for manifest glaucoma were defined as RNFL ≤ 75 μm, interocular asymmetry ≥ 15 μm, or visual field defects; manifest ECCD loss as ≥ 20% interocular difference or ECCD ≤ 1500 cells/mm². Initial treatment response (ITR) was defined as IOP normalization and inflammation reduction within 2 weeks. Flare-up rates were compared between high-dose (2% ganciclovir ≥ QID) and low-dose (2% ganciclovir ≤ TID) topical regimens. The mean age was 56.5 ± 15.5 years, and 82.1% had unilateral disease. Median diagnostic delay was 33 months; 20.9% required repeat aqueous taps. ITR was achieved in 87.6%. High-dose topical antivirals reduced flare-ups 2.25-fold vs. low-dose regimens (0.471 vs. 1.058 events/eye-year; relative risk = 0.45). Glaucoma rose from 30.3% to 62.0% and ECCD loss from 27.8% to 57.0% during follow-up. Kaplan-Meier analysis showed a median time of 9 years from symptom-onset to manifest glaucoma. Above-midline KPs were inversely associated with peak IOP on linear regression (p < 0.001). CMV AU poses significant long-term structural risk despite good short-term control. Early criteria-based treatment and high-dose antivirals reduce relapse, while lifelong maintenance is required in eyes with advanced disease.
2026-06-27 | Statin Intensity and the Risk of Noninfectious Uveitis.
To evaluate whether the 5-year risk of incident noninfectious uveitis (NIU) is associated with the intensity of statin therapy in patients with hyperlipidemia. Retrospective, propensity score-matched cohort study. Patients diagnosed with hyperlipidemia within a nationwide federated electronic medical record network (TriNetX). Patients initiating high-, medium-, or low-intensity statin therapy were compared to two mutually exclusive control cohorts: an active comparator control (proton pump inhibitor [PPI] users) and an unexposed control cohort. Patients with prior uveitis or any history of fibrate use were excluded. Each statin intensity cohort underwent 1:1 propensity score matching with both control groups to balance baseline demographics and systemic comorbidities. 5-year hazard ratios (HR) with 95% confidence intervals (CI) for incident overall NIU, anterior uveitis, and posterior/panuveitis. Prior to matching, the study identified 32,434 high-intensity, 16,955 medium-intensity, and 4,843 low-intensity statin users. Following matching, high-intensity statin therapy was associated with a significantly reduced 5-year risk of overall NIU compared to the unexposed control (HR 0.81, 95% CI: 0.69-0.95) with a statistically significant reduction against the active control (HR 0.73, 95% CI: 0.57-0.94). This protective effect was primarily driven by significant reductions in anterior uveitis against both the unexposed control (HR 0.77, 95% CI: 0.65-0.92) and the active control (HR 0.72, 95% CI: 0.55-0.94). Medium-intensity statin therapy yielded a significant risk reduction for overall NIU (HR 0.81, 95% CI: 0.66-0.99) and anterior uveitis (HR 0.84, 95% CI: 0.68-1.03) against the unexposed control but did not reach statistical significance against the active control. Low-intensity statin regimens did not significantly alter the risk of NIU or any anatomical subtype across either comparison group. Negative control outcome analysis demonstrated null associations across all cohorts, supporting the validity of the observed findings. Statin therapy is associated with an intensity-dependent reduction in the 5-year risk of noninfectious uveitis. High-intensity statin regimens confer the most robust and sustained protective benefit, suggesting that higher-potency dosing is necessary to achieve clinically significant modulation of ocular inflammation.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Anterior uveitis.
2 orphan drug designations for Anterior uveitis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
E. Coli heat-shock protein 70 with bovine retinal S-antigen | proteins | EMA | 2006-01-24 | — | Biotech Tools SA |
AI-RSA | small molecules | FDA | 1992-10-08 | — | AutoImmune, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.